Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bargay

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
British Journal of Haematology|December 12, 2001
Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre studyR Martino, M D Caballero, C Canals, et al.
Bone Marrow Transplantation|September 10, 2005
Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH)M A Diaz, M Gonzalez-Vicent, M E Gonzalez, et al.
Leukemia|September 28, 2013
MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemiaM Díaz-Beyá, S Brunet, J Nomdedéu, et al.
Transplantation Proceedings|March 20, 2003
Phase I/II trials of autologous peripheral blood stem cell transplantation in autoimmune diseases resistant to conventional therapy: preliminary results from the Spanish experienceI Espigado, A Marín-Niebla, M Rovira, et al.
Clinical Epigenetics|January 15, 2021
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survivalM Cabezón, R Malinverni, J Bargay, et al.
Leukemia|May 7, 2015
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registryT Bernal, P Martínez-Camblor, J Sánchez-García, et al.
Leukemia Research|January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome predictionF Ramos, S Thépot, L Pleyer, et al.
Transfusion|March 10, 2001
Donor age-related differences in PBPC mobilization with rHuG-CSFJ de La Rubia, M A Díaz, A Verdeguer, et al.
Annals of Hematology|February 17, 2020
Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies)E Bussaglia, M Pratcorona, M Carricondo, et al.
Leukemia|April 16, 2013
Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AMLJ F Nomdedéu, M Hoyos, M Carricondo, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
British Journal of Haematology|December 12, 2001
Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre studyR Martino, M D Caballero, C Canals, et al.
Bone Marrow Transplantation|September 10, 2005
Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH)M A Diaz, M Gonzalez-Vicent, M E Gonzalez, et al.
Leukemia|September 28, 2013
MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemiaM Díaz-Beyá, S Brunet, J Nomdedéu, et al.
Transplantation Proceedings|March 20, 2003
Phase I/II trials of autologous peripheral blood stem cell transplantation in autoimmune diseases resistant to conventional therapy: preliminary results from the Spanish experienceI Espigado, A Marín-Niebla, M Rovira, et al.
Clinical Epigenetics|January 15, 2021
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survivalM Cabezón, R Malinverni, J Bargay, et al.
Leukemia|May 7, 2015
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registryT Bernal, P Martínez-Camblor, J Sánchez-García, et al.
Leukemia Research|January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome predictionF Ramos, S Thépot, L Pleyer, et al.
Transfusion|March 10, 2001
Donor age-related differences in PBPC mobilization with rHuG-CSFJ de La Rubia, M A Díaz, A Verdeguer, et al.
Annals of Hematology|February 17, 2020
Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies)E Bussaglia, M Pratcorona, M Carricondo, et al.
Leukemia|April 16, 2013
Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AMLJ F Nomdedéu, M Hoyos, M Carricondo, et al.
Pageof 4